UK launches scheme to boost dementia trial participation
A UK initiative to tackle the "historically low" numbers of people taking part in dementia clinical trials has been launched with £20 million ($26 million) in funding from the government.
Newsletters and Deep Dive digital magazine
A UK initiative to tackle the "historically low" numbers of people taking part in dementia clinical trials has been launched with £20 million ($26 million) in funding from the government.
Activist investor Starboard Value has launched a broadside against Pfizer's leadership under chief executive Albert Bourla, claiming at least $20 billion in value – and possibly as much as
Otsuka is hoping to file for approval of its anti-APRIL antibody sibeprenlimab as a treatment for kidney disorder IgA nephropathy (IgAN) after the drug hit the target in a phase 3 trial.
The proportion of commercially sponsored clinical trials run in Europe almost halved over the last 10 years and is now trailing China, whose share has doubled in the same period.
After emerging from the shadows with a $100 million Series A in April, Seaport Therapeutics has moved swiftly to shore up its finances with a $225 million second round to fund the developme
Editor's Picks
Newsletters and Deep Dive
digital magazine